Kodanikupalga vajadus ning selle rakendamise mõju tööjõupakkumisele Eesti näitel

14484 sequence. (JPEG 74 kb

Additional file 3: of PHENOS: a high-throughput and flexible tool for microorganism growth phenotyping on solid media

A Validation by paraquat QTLs (xlsx). Full list of QTL intervals and their details. B Validation by paraquat QTLs measurements (zip). Initial DAT and csv files. (XLSX 53 kb

CpG methylation in Region 1 of the <i>SLC6a2</i> promoter in humans.

<p>The methylation status of <i>SLC6a2</i> promoter Region 1 (-515 bp to -225 bp) in leukocytes was analysed by bisulphite sequencing in 4 healthy subjects compared to 4 subjects with MDD or panic disorder (#1-4). <b>A</b>) A schematic representation of Region 1. The individual CpG sites analysed in Region 1 are indicated as enlarged boxes with their positioning relative to the transcription start site (+1) indicated with an arrow. <b>B</b>) Bisulphite sequencing data for MDD, panic disorder and healthy controls. Each row of boxes represents a single cloned allele, and each box represents a single CpG dinucleotide. Black boxes indicate methylated cytosine residues, white boxes indicate unmethylated cytosine residues. For healthy subjects #1-4, 10 individual clones were sequenced. For MDD subjects #1-4, between 7 and 12 individual clones were sequenced. For panic disorder subjects #1-4, between 5 and 9 individual clones were sequenced for each subject.</p

Analysis of methylation in Region A pre- and post-SSRI treatment.

<div><p>Representation of the methylation percentages for CpG sites in Region A of the NET gene determined by EpiTYPER analysis in human leukocytes pre- and post-SSRI treatment. CpG sites are numbered 5’- 3’ along the X-axis, with percentage methylation on the Y-axis. Usable data could not be obtained for all CpG sites for all samples. Samples pre- and post-SSRI treatment exhibited a similar methylation profile across the region, and no differences in average methylation of CpG sites in response to SSRI treatment were determined to be significant by paired t-test. </p> <p>*Statistically significant site-specific difference in methylation with SSRI treatment.</p></div

CpG methylation of Region B of the human SLC6a2 promoter.

<p>Representation of the methylation percentages for CpG sites in Region B of the <i>SLC6a2</i> gene determined by EpiTYPER analysis. CpG sites are numbered 5’- 3’ along the X-axis, with percentage methylation on the Y-axis. Usable data could not be obtained for all CpG sites for all samples. The overall methylation of Region B in subjects with MDD was determined to be significantly greater than all other groups (p<0.05). </p

Analysis of methylation in Region B pre- and post-SSRI treatment.

<p>Representation of the methylation percentages for CpG sites in Region B of the NET gene determined by EpiTYPER analysis in human leukocytes pre- and post-SSRI treatment. CpG sites are numbered 5’- 3’ along the X-axis, with percentage methylation on the Y-axis. Usable data could not be obtained for all CpG sites for all samples. Samples pre- and post-SSRI treatment exhibited no significant difference in methylation profile across the region. </p

CpG methylation in Region 2 of the <i>SLC6a2</i> promoter in humans.

<p>The methylation status of the <i>SLC6a2</i> promoter Region 2 (-180 bp to +167 bp) was analysed by bisulphite sequencing in 4 healthy subjects compared to 4 subjects with MDD and panic disorder. <b>A</b>) A schematic representation of Region 2. The individual CpG sites analysed in Region 2 are indicated as enlarged boxes with their positioning relative to the transcription start site (+1) indicated with an arrow. <b>B</b>) Bisulphite sequencing data are presented as in Figure 1. For healthy subjects #1-4, 10 individual clones were sequenced. For MDD subjects #1-4, between 8 and 9 individual clones were sequenced. A different MDD patient (#5) replaced sample #3 due to insufficient sample. For panic disorder subjects #1-4, between 8 and 10 individual clones were sequenced.</p

Technoeconomic Analysis for the Production of Mixed Alcohols via Indirect Gasification of Biomass Based on Demonstration Experiments

An integrated biomass-to-mixed alcohol process was demonstrated at the pilot scale, including indirect gasification, tar and hydrocarbon reforming, gas conditioning, and gas to liquids operations. Additional bench-scale experiments were conducted to gather insights into reforming and fuel synthesis operations under more extensive conditions. Data from these experiments were combined with tools and knowledge owned by industrial partnersRentech and The Dow Chemical Companyto validate a conceptual commercial-scale cellulosic ethanol refinery. Results suggest that both reforming and mixed alcohol processes are scalable and economical, with a modeled mature plant ethanol production cost of $0.54/L ($0.82/L of gasoline equivalent). Sustainability metrics for the conversion process are also presented